Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

211 Mt. Airy Road
Basking Ridge, NJ 07920

Tel: (908) 992-6400

Visit website

NEWS

Ultomiris has been approved by FDA for commerciali

Business

AstraZeneca and Daiichi Sankyo Sign $6.9 Billion Deal for a Single Cancer Drug

AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).

March 29, 2019

2 min read

Mark Terry

Business

Let’s Make a Deal: Veracyte & J&J, Vertex & Arbor, Esperion & Daiichi Sankyo and More

With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.

January 4, 2019

4 min read

Mark Terry

Drug Development

The 20 Hottest Pipeline Drugs to Watch in 2019

EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.

December 18, 2018

6 min read

Mark Terry

Pictured: Office building science collage

Job Trends

The Top 12 Biopharma Companies Hiring Now

Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.

September 5, 2018

1 min read

Editorial Staff

Business

CEOs, Directors and Other Senior Executives Tapped by Biotech

Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.

May 21, 2018

7 min read

Alex Keown

Close up top view of young business people putting their hands together. Stack of hands. Unity and teamwork concept.

Policy

Zymeworks and Daiichi Sankyo Strike Second Licensing Agreement for Bispecific Antibody Platforms

Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.

May 15, 2018

2 min read

Alex Keown

Drug Development

European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.

February 23, 2018

3 min read

Mark Terry